The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Indian drugmaker Sun Industries’ Leqselvi ...

Swiss neurotechnology firm MindMaze Therapeutics has appointed healthtech executive Zach Henderson as chief executive, as the ...

US biotech BridgeBio (Nasdaq: BBIO) reported positive interim Phase III data for BBP-418 in limb-girdle muscular dystrophy, ...

The US Food and Drug Administration (FDA) yesterday launched a new unified platform for analyzing adverse event reports. This ...

Cambridge, UK based 4basebio, a specialist in synthetic DNA manufacturing, today announced the appointment of Scott Lorimer as chief operating officer (COO), effective immediately.

US biotech Lexicon Pharmaceuticals (Nasdaq: LXRX) said a post hoc analysis of clinical trial data suggests sotagliflozin improved several measures of glycemic control after one year in people with ...

Veristat, a US headquartered clinical research organization (CRO) and consultancy specializing in complex studies, announced expanded regulatory and clinical trial services to international ...

US biotech Vima Therapeutics has secured $40 million in a series A extension to support development of its oral movement-disorder therapy VIM0423, bringing the total financing round to $100 million.

French drugmaker Ipsen has announced the appointment of Michelle Werner as executive vice president, president of North America, effective March 23.

Swiss specialty drugmaker Santhera Pharmaceuticals today provides a trading update for the fiscal year 2025. The firm’s share dipped 3.2% to 16.50 francs following the announcement.

Spanish dermatology specialist Almirall today inaugurated new offices in Jing’an, Shanghai, establishing a presence dedicated to life science innovation and business development in medical dermatology ...

A late-stage biopharmaceutical company developing combination therapies for cardiometabolic diseases. George Medicines focuses on single-pill, fixed-dose combinations of existing drugs designed to ...